Kaifu Biomedicine

Kaifu Biomedicine is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of innovative therapies for autoimmune and inflammatory diseases. The company focuses on targeting key pathways in the immune system, such as the IL-17 and IL-23 axes, to treat conditions like psoriasis and ankylosing spondylitis. Its lead programs include small molecule inhibitors and monoclonal antibodies designed to provide more effective and convenient treatment options for patients. Kaifu Biomedicine leverages its internal R&D capabilities to advance a pipeline of candidates through clinical trials in the Chinese and global markets.